3-(2-甲酰基-1H-吡咯-1-基)苯甲腈 | 209958-45-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 3-(2-甲酰基-1H-吡咯-1-基)苯甲腈
• 英文名称: 1-(3-cyanophenyl)pyrrole-2-carboxaldehyde
• 英文别名: 3-(2-formyl-pyrrol-1-yl)-benzonitrile；3-(2-formylpyrrol-1-yl)benzonitrile
• CAS: 209958-45-2
• 化学式: C₁₂H₈N₂O
• mdl: MFCD03086206
• 分子量: 196.208
• InChiKey: VDERABPBRHOLJS-UHFFFAOYSA-N

物化性质

• 熔点：
  145°C
• 沸点：
  377.4±22.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R20/21/22
• 危险品运输编号：
  UN 3439
• 海关编码：
  2933990090
• 安全说明：
  S36/37

反应信息

• 作为反应物：
  描述：

  3-(2-甲酰基-1H-吡咯-1-基)苯甲腈 在 potassium permanganate 、 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氯化碳 、 丙酮 为溶剂， 生成 4-Bromo-1-(3-cyano-phenyl)-1H-pyrrole-2-carboxylic acid
  参考文献：
  名称：

  Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

  摘要：

  Factor Xa (fXa) plays a critical role in the coagulation cascade, serving as the point of convergence of the intrinsic and extrinsic pathways. Together with nonenzymatic cofactor Va and Ca2+ on the phospholipid surface of platelets or endothelial cells, factor Xa forms the prothrombinase complex, which is responsible for the proteolysis of prothrombin to catalytically active thrombin. Thrombin, in turn, catalyzes the cleavage of fibrinogen to fibrin, thus initiating a process that ultimately leads to clot formation. Recently, we reported on a series of isoxazoline and isoxazole monobasic noncovalent inhibitors of factor Xa which show good potency in animal models of thrombosis. In this paper, we wish to report on the optimization of the heterocyclic core, which ultimately led to the discovery of a novel pyrazole SN429 (2b; fXa K-i = 13 pM). We also report on our efforts to improve the oral bioavailability and pharmacokinetic profile of this series while maintaining subnanomolar potency and in vitro selectivity. This was achieved by replacing the highly basic benzamidine P-1 with a less basic benzylamine moiety. Further optimization of the pyrazole core substitution and the biphenyl P-4 culminated in the discovery of DPC423 (17h), a highly potent, selective, and orally active factor Xa inhibitor which was chosen for clinical development.

  DOI：

  10.1021/jm000409z
• 作为产物：
  描述：

  间氨基苯甲腈 在 溶剂黄146 、 三氯氧磷 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 0.5h， 生成 3-(2-甲酰基-1H-吡咯-1-基)苯甲腈
  参考文献：
  名称：

  Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

  摘要：

  Factor Xa (fXa) plays a critical role in the coagulation cascade, serving as the point of convergence of the intrinsic and extrinsic pathways. Together with nonenzymatic cofactor Va and Ca2+ on the phospholipid surface of platelets or endothelial cells, factor Xa forms the prothrombinase complex, which is responsible for the proteolysis of prothrombin to catalytically active thrombin. Thrombin, in turn, catalyzes the cleavage of fibrinogen to fibrin, thus initiating a process that ultimately leads to clot formation. Recently, we reported on a series of isoxazoline and isoxazole monobasic noncovalent inhibitors of factor Xa which show good potency in animal models of thrombosis. In this paper, we wish to report on the optimization of the heterocyclic core, which ultimately led to the discovery of a novel pyrazole SN429 (2b; fXa K-i = 13 pM). We also report on our efforts to improve the oral bioavailability and pharmacokinetic profile of this series while maintaining subnanomolar potency and in vitro selectivity. This was achieved by replacing the highly basic benzamidine P-1 with a less basic benzylamine moiety. Further optimization of the pyrazole core substitution and the biphenyl P-4 culminated in the discovery of DPC423 (17h), a highly potent, selective, and orally active factor Xa inhibitor which was chosen for clinical development.

  DOI：

  10.1021/jm000409z

文献信息

• Application of oxime-diversification to optimize ligand interactions within a cryptic pocket of the polo-like kinase 1 polo-box domain
  作者：Xue Zhi Zhao、David Hymel、Terrence R. Burke

  DOI：10.1016/j.bmcl.2016.08.098

  日期：2016.10

  potent previously known polo-like kinase 1 (Plk1) polo-box domain (PBD) binding inhibitors. This improved binding may result by accessing a newly identified auxiliary region proximal to a key hydrophobic cryptic pocket on the surface of the protein. Our findings could have general applicability to the design of PBD-binding antagonists.

  通过涉及使用基于肟连接的策略初步筛选一组87个醛的过程，我们能够实现比最有效的先前已知的polo-like激酶1（Plk1）polo-box的亲和力提高数倍。域（PBD）结合抑制剂。这种改善的结合可以通过接近蛋白质表面上关键疏水隐窝的新近识别出的辅助区域来实现。我们的发现可能普遍适用于PBD结合拮抗剂的设计。
• [EN] ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] DERIVES D'ANABASEINE UTILES POUR LE TRAITEMENT DE MALADIES NEURODEGENERATIVES
  申请人：MEMORY PHARM CORP

  公开号：WO2004019943A1

  公开（公告）日：2004-03-11

  The compounds of the present invention are of formula (I): wherein A, R3, R4 is as defined herein, are useful as ligands for nicotinic receptors.

  本发明的化合物的化学式为（I）：其中A、R3、R4如本文所定义，可用作尼古丁受体的配体。
• [EN] NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS<br/>[FR] COMPOSES HETEROAROMATIQUES CONTENANT DE L'AZOTE, UTILISES EN TANT QU'INHIBITEURS DU FACTEUR Xa
  申请人：DU PONT PHARMACEUTICALS COMPANY

  公开号：WO1998028269A1

  公开（公告）日：1998-07-02

  (EN) The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula (I) or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D may be C(=NH)NH2, which are useful as inhibitors of factor Xa.(FR) La présente invention se rapporte à des composés hétéroaromatiques contenant de l'azote et à des dérivés de tels composés représentés par la formule (I), ou à des sels ou bioprécurseurs pharmaceutiquement acceptables de ces composés utiles en tant qu'inhibiteurs du facteur Xa. Dans la formule (I), J est N ou NH et D peut être C(=NH)NH2.

  (中) 本申请描述了含氮杂环芳香族化合物及其衍生物的公式(I)，或其药学上可接受的盐或前药形式，其中J为N或NH，D可能是C(=NH)NH2，这些化合物可用作凝血因子Xa的抑制剂。
• Heterocyclic compounds, methods for the preparation thereof, and uses thereof
  申请人：MEMORY PHARMACEUTICALS CORP.

  公开号：US20040229868A1

  公开（公告）日：2004-11-18

  The compounds of the present invention are of formula I: 1 wherein A, R 3 , R 4 is as defined herein, are useful as ligands for nicotinic receptors.

  本发明的化合物的化学式为I:1，其中A、R3、R4如本文所定义，可用作尼古丁受体的配体。
• HETEROCYCLIC COMPOUNDS, METHODS FOR THE PREPARATION THEREOF, AND USES THEREOF
  申请人：Herbert Brian

  公开号：US20100173891A1

  公开（公告）日：2010-07-08

  The compounds of the present invention are of formula I: wherein A, R 3 , R 4 is as defined herein, are useful as ligands for nicotinic receptors.

  本发明的化合物为公式I：其中A、R3、R4如此处所定义，可用作尼古丁受体的配体。